Death receptor-ligand systems in cancer, cell death, and inflammation

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 5, 2013, Pages

  Walczak, Henning ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL; APOPTOSIS; DRUG DEVELOPMENT; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MITOCHONDRION; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; DRUG DISCOVERY; HUMANS; INFLAMMATION; MICE; MITOCHONDRIA; NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891656477     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a008698     Document Type: Article

References (149)

1. Ackery A., Robins S, Fehlings MG. 2006. Inhibition of Fasmediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 23: 604-616.
2. Alderson M.R., Armitage RJ, Maraskovsky E, Tough TW, Roux E., Schooley K, Ramsdell F, Lynch DH. 1993. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178: 2231-2235.
3. Alderson M.R., Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K., Miller RE, Lynch DH. 1994. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol 6: 1799-1806.
4. Alderson M.R., Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley K.A., Goodwin RG, Smith CA, Ramsdell F, Lynch DH. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71-77.
5. Ashkenazi A., Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
6. Baker M.B., Altman NH, Podack ER, Levy RB. 1996. The role of cell-mediated cytotoxicity in acuteGVHDafter MHCmatched allogeneic bone marrow transplantation in mice. J Exp Med 183: 2645-2656.
7. Balkwill F. 2009. Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
8. Barnhart B.C., Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. 2004. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23: 3175-3185.
9. Berke G. 1995. The CTL's kiss of death. Cell 81: 9-12.
10. Bodmer J.L., Burns K, Schneider P, Hofmann K, Steiner V, Thome M., Bornand T, Hahne M, Schroter M, Becker K, et al. 1997. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 6: 79-88.
11. Boldin M.P., Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y., Camonis JH, Wallach D. 1995a. Self-association of the "death domains of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 270: 387-391.
12. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. 1995b. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270: 7795-7798.
13. Boldin M.P., Goncharov TM, Goltsev YV, Wallach D. 1996. Involvement ofMACH, a novelMORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 85: 803-815.
14. Braun M.Y., Lowin B, French L, Acha-Orbea H, Tschopp J. 1996. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183: 657-661.
15. Brunner T., Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F., Martin SJ, Force WR, Lynch DH, Ware CF, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444.
16. Budd R.C., Yeh WC, Tschopp J. 2006. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 6: 196-204.
17. Carswell E.A., Old LJ, Kassel RL, Green S, Fiore N, Williamson B. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 72: 3666-3670.
18. Cerretti D.P., Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet T.A., March CJ, Kronheim SR, Druck T, Cannizzaro L.A., et al. 1992. Molecular cloning of the interleukin-1b converting enzyme. Science 256: 97-100.
19. Chen L., Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner J.R., Fu YX, Romero IL, Lengyel E, et al. 2010. CD95 promotes tumour growth. Nature 465: 492-496.
20. Chinnaiyan A.M., O'Rourke K, Tewari M, Dixit VM. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
21. Chinnaiyan A.M., O'Rourke K, Yu GL, Lyons RH, Garg M, Duan D.R., Xing L, Gentz R, Ni J, Dixit VM. 1996. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274: 990-992.
22. Cho Y.S., Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. 2009. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137: 1112-1123.
23. Creagh E.M., Martin SJ. 2001. Caspases: Cellular demolition experts. Biochem Soc Trans 29: 696-702.
24. Demjen D., Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C., Hirt UA, Walczak H, Falk W, Essig M, et al. 2004. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 10: 389-395.
25. Desbarats J., Newell MK. 2000. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 6: 920-923.
26. + T cell responses to Fas engagement. Proc Natl Acad Sci 96: 8104-8109.
27. Dhein J., Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. 1992. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 149: 3166-3173.
28. Dhein J., Walczak H, Baumler C, Debatin KM, Krammer PH. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/ CD95). Nature 373: 438-441.
29. Dickens L.S., Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, Schwabe JW, Cain K, Macfarlane M. 2012. A death effector domain chain DISC model reveals a crucial role for Caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell 47: 291-305.
30. Dillon C.P., Oberst A, Weinlich R, Janke LJ, Kang TB, Ben-Moshe T., Mak TW, Wallach D, Green DR. 2012. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep 1: 401-407.
31. Ehl S., Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R. 1996. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol 156: 2357-2360.
32. Ehrhardt H., Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kB. Oncogene 22: 3842-3852.
33. Freiberg R.A., Spencer DM, Choate KA, Duh HJ, Schreiber SL, Crabtree GR, Khavari PA. 1997. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 108: 215-219.
34. Galle P.R., Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230.
35. Ganten T.M., Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K., Walczak H. 2005. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597.
36. Ganten T.M., Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P., Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H. 2006. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12: 2640-2646.
37. Gerlach B., Cordier SM, Schmukle AC, Emmerich CH, Rieser E., Haas TL, Webb AI, Rickard JA, Anderton H, Wong W.W., et al. 2011. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471: 591-596.
38. Green DR. 2010. Cancer: A wolf in wolf 's clothing. Nature 465: 433.
39. Green DR. 2013. Mitos, MOMP, and death. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a008706.
40. Gross A., Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. 1999. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163.
41. Gunther C., Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, Waldner MJ, Hedrick SM, Tenzer S, Neurath M.F., et al. 2012. Caspase-8 regulates TNF-a-induced epithelial necroptosis and terminal ileitis. Nature 477: 335-339.
42. Hall SS. 1997. A commotion in the blood: Life, death, and the immune system. Holt, New York.
43. He S., Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. 2009. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-a. Cell 137: 1100-1111.
44. Hitomi J., Christofferson DE, Ng A, Yao J, Degterev A, Xavier R.J., Yuan J. 2008. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135: 1311-1323.
45. Holler N., Zaru R, Micheau O, Thome M, Attinger A, Valitutti S., Bodmer JL, Schneider P, Seed B, Tschopp J. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1: 489-495.
46. Irmler M., Thome M, Hahne M, Schneider P, Hofmann K, Steiner V., Bodmer JL, Schroter M, Burns K, Mattmann C, et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195.
47. Itoh N., Nagata S. 1993. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268: 10932-10937.
48. Itoh N., Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M., Hase A, Seto Y, Nagata S. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243.
49. Jeremias I., Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J., Boekstegers P, Debatin KM. 2000. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation 102: 915-920.
50. Jost P.J., Grabow S, Gray D, McKenzie MD, Nachbur U, Huang D.C., Bouillet P, Thomas HE, Borner C, Silke J, et al. 2009. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035-1039.
51. Ju S.T., Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger B.Z., Marshak-Rothstein A. 1995. Fas(CD95)/ FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
52. Kaiser W.J., Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer L.P., Hakem R, Caspary T, Mocarski ES. 2011. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368-372.
53. Kavuri S.M., Geserick P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D., Gollnick H, Neumann M, Wajant H, Leverkus M. 2011. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95-and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem 286: 16631-16646.
54. Kennedy N.J., Kataoka T, Tschopp J, Budd RC. 1999. Caspase activation is required for T cell proliferation. J Exp Med 190: 1891-1896.
55. Kischkel F.C., Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588.
56. Kischkel F.C., Lawrence DA, Chuntharapai A, Schow P, Kim K.J., Ashkenazi A. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADDand caspase-8 to death receptors 4 and 5. Immunity 12: 611-620.
57. Kischkel F.C., Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P., Gazdar A, Blenis J, Arnott D, Ashkenazi A. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639-46646.
58. Kitson J., Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, Grinham C.J., Brown R, Farrow SN. 1996. A death-domain-containing receptor that mediates apoptosis. Nature 384: 372-375.
59. Kleber S., Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O., Thiemann M, Mueller W, Sykora J, Kuhn A, et al. 2008. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248.
60. Komander D., Clague MJ, Urbe S. 2009a. Breaking the chains: Structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10: 550-563.
61. Komander D., Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson K.D., Barford D. 2009b. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 10: 466-473.
62. Kondo T., Suda T, Fukuyama H, Adachi M, Nagata S. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3: 409-413.
63. Koschny R., Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A., Stremmel W, Walczak H. 2007. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45: 649-658.
64. Kovalenko A., Kim JC, Kang TB, Rajput A, Bogdanov K, Dittrich-Breiholz O, Kracht M, Brenner O, Wallach D. 2009. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J Exp Med 206: 2161-2177.
65. Lawrence D., Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B., Hillan K, Totpal K, DeForge L, Schow P, et al. 2001. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385.
66. Lee P., Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. 2003. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 284: H456-H463.
67. Lemke J., Noack A, Adam D, Tchikov V, Bertsch U, Roder C, Schutze S., Wajant H, Kalthoff H, Trauzold A. 2010. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J MolMed (Berl) 88: 729-740.
68. Lo Y.C., Lin SC, Rospigliosi CC, Conze DB, Wu CJ, Ashwell J.D., Eliezer D, Wu H. 2009. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 33: 602-615.
69. Loetscher H., Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H., Lesslauer W. 1990. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61: 351-359.
70. Lowin B., Beermann F, Schmidt A, Tschopp J. 1994a. A null mutation in the perforin gene impairs cytolytic T lymphocyte-and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci 91: 11571-11575.
71. Lowin B., Hahne M, Mattmann C, Tschopp J. 1994b. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652.
72. Marsters S.A., Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. 1996. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 6: 750-752.
73. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J., Schenkel J, Herdegen T, Debatin KM. 1999. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19: 3809-3817.
74. Micheau O., Tschopp J. 2003. Induction of TNF receptor Imediated apoptosis via two sequential signaling complexes. Cell 114: 181-190.
75. Migone T.S., Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong J.S., Perry JW, Chen SF, Zhou JX, et al. 2002. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492.
76. Miwa K., Hashimoto H, Yatomi T, Nakamura N, Nagata S, Suda T. 1999. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 11: 925-931.
77. Muzio M., Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A., Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R., et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death-inducing signaling complex. Cell 85: 817-827.
78. Nauts H.C., Swift WE, Coley BL. 1946. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6: 205-216.
79. Nauts H.C., Fowler GA, Bogatko FH. 1953. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276: 1-103.
80. Newsom-Davis T, Prieske S, Walczak H. 2009. Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607-623.
81. Nikolaev A., McLaughlin T, O'Leary DD, Tessier-Lavigne M. 2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981-989.
82. Oberst A., Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. 2011. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363-367.
83. Oehm A., Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, et al. 1992. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/ nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267: 10709-10715.
84. Ogasawara J., Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. 1993. Lethal effect of the anti-Fas antibody inmice. Nature 364: 806-809.
85. Owen-Schaub LB, Meterissian S, Ford RJ. 1993. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother Emphasis Tumor Immunol 14: 234-241.
86. Oyaizu T., Shikata N, Senzaki H, Matsuzawa A, Tsubura A. 1997. Studies on the mechanism of dimethylnitrosamine-induced acute liver injury in mice. Exp Toxicol Pathol 49: 375-380.
87. Pan G., Ni J, Wei YF, Yu G, Gentz R, Dixit VM. 1997a. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818.
88. Pan G., O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. 1997b. The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113.
89. Pan G., Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal B.B., Ni J, Dixit VM. 1998. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 431: 351-356.
90. Parrish A.B., Freel CD, Kornbluth S. 2013. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect. a008672.
91. Peter M.E., Krammer PH. 1998. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10: 545-551.
92. Peter M.E., Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell M.K., Owen LB, Pope RM, Tschopp J, Wajant H, et al. 2007. The CD95 receptor: Apoptosis revisited. Cell 129: 447-450.
93. Pitti R.M., Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690.
94. Pop C., Salvesen GS. 2009. Human caspases: Activation, specificity, and regulation. J Biol Chem 284: 21777-21781.
95. Rahighi S., Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R., Kensche T, Uejima T, Bloor S, Komander D, et al. 2009. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kB activation. Cell 136: 1098-1109.
96. Reap E.A., Sobel ES, Cohen PL, Eisenberg RA. 1993. Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice. J Exp Med 177: 69-78.
97. Rieser E., Schmukle AC, Walczak H. 2012. Linear ubiquitination: A newly discovered regulator of cell signalling. Trends Biochem Sci 24: 229-231.
98. Roder C., Trauzold A, Kalthoff H. 2011. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 90: 450-455.
99. Roths J.B., Murphy ED, Eicher EM. 1984. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159: 1-20.
100. Salvesen G.S., Riedl SJ. 2008. Caspase mechanisms. Adv Exp Med Biol 615: 13-23.
101. Sancho-Martinez I, Martin-Villalba A. 2009. Tyrosine phosphorylation and CD95: A FAScinating switch. Cell Cycle 8: 838-842.
102. Schall T.J., Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T., Granger GA, Lentz R, Raab H, et al. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361-370.
103. Schleich K., Warnken U, Fricker N, Ozturk S, Richter P, Kammerer K., Schnolzer M, Krammer PH, Lavrik IN. 2012. Stoichiometry of the CD95 death-inducing signaling complex: Experimental and modeling evidence for a death effector domain chain model. Mol Cell 47: 306-319.
104. Screaton G.R., Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. 1997a. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 7: 693-696.
105. Screaton G.R., Xu XN, Olsen AL, Cowper AE, Tan R, McMichael AJ, Bell JI. 1997b. LARD: A new lymphoidspecific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci 94: 4615-4619.
106. Shear M.J., Perrault A. 1944. Achemical treatment of tumors. IX. Reactions of micewith primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Natl Cancer Inst 44: 461-476.
107. Sheridan J.P., Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D., Ramakrishnan L, Gray CL, Baker K, Wood W.I., et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821.
108. Simonet W.S., Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R., Nguyen HQ, Wooden S, Bennett L, Boone T, et al. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
109. Smith C.A., Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R., Dower SK, Cosman D, Goodwin RG. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019-1023.
110. Sprick M.R., Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer P.H., Walczak H. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
111. Sprick M.R., Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. 2002. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21: 4520-4530.
112. Strand S., Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H, Mariani SM, Hack V, Stremmel W., et al. 1998. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 4: 588-593.
113. Strand S., Strand D, Seufert R, Mann A, Lotz J, Blessing M, Lahn M., Wunsch A, Broering DC, Hahn U, et al. 2004. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology 126: 849-858.
114. Suda T., Nagata S. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179: 873-879.
115. Suda T., Takahashi T, Golstein P, Nagata S. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178.
116. Takahashi T., Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976.
117. Tartaglia L.A., Ayres TM, Wong GH, Goeddel DV. 1993. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853.
118. Taylor P.C., Feldmann M. 2009. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-582.
119. Thome M., Schneider P, Hofmann K, Fickenscher H, Meinl E., Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M., et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517-521.
120. Thornberry N.A., Bull HG, Calaycay JR, Chapman KT, Howard A.D., Kostura MJ, Miller DK, Molineaux SM, Weidner J.R., Aunins J, et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1b processing in monocytes. Nature 356: 768-774.
121. Tracey K.J., Lowry SF, Cerami A. 1988. Cachetin/TNF-a in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 138: 1377-1379.
122. Trauth B.C., Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin K.M., Krammer PH. 1989. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science 245: 301-305.
123. Vandenabeele P., Galluzzi L, Vanden Berghe T, Kroemer G. 2010. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 11: 700-714.
124. van Raam BJ, Salvesen GS. 2012. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: The caspase-8 dimer controls cell fate. Biochim Biophys Acta 1824: 113-122.
125. Varfolomeev E., Maecker H, Sharp D, Lawrence D, Renz M, Vucic D., Ashkenazi A. 2005. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280: 40599-40608.
126. Via C.S., Nguyen P, Shustov A, Drappa J, Elkon KB. 1996a. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157: 5387-5393.
127. Via C.S., Rus V, Nguyen P, Linsley P, Gause WC. 1996b. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 157: 4258-4267.
128. Vince J.E., Wong WW, Gentle I, Lawlor KE, Allam R, O'Reilly L, Mason K, Gross O, Ma S, Guarda G, et al. 2012. Inhibitor of apoptosis proteins limit RIP3 kinasedependent interleukin-1 activation. Immunity 36: 215-227.
129. Vogt M., Bauer MK, Ferrari D, Schulze-Osthoff K. 1998. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett 429: 67-72.
130. Wajant H., Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65.
131. Walczak H. 2011. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev 244: 9-28.
132. Walczak H., Krammer PH. 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256: 58-66.
133. Walczak H., Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh J.Y., Boiani N, Timour MS, Gerhart MJ, Schooley K.A., Smith CA, et al. 1997. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397.
134. Walczak H., Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M., Chin W, Jones J, Woodward A, Le T, et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
135. Wallach D., Kovalenko A, Kang TB. 2012. ""Necrosome"-induced inflammation: Must cells die for it? Trends Immunol 32: 505-509.
136. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins N.A., Nagata S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
137. Welz P.S., Wullaert A, Vlantis K, Kondylis V, Fernandez-Majada V., Ermolaeva M, Kirsch P, Sterner-Kock A, van Loo G., Pasparakis M. 2011. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477: 330-334.
138. Wiley S.R., Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl J.K., Sutherland GR, Smith TD, Rauch C, Smith C.A., et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
139. Williams R.O., Feldmann M, Maini RN. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci 89: 9784-9788.
140. Wilson N.S., Dixit V, Ashkenazi A. 2009. Death receptor signal transducers: Nodes of coordination in immune signaling networks. Nat Immunol 10: 348-355.
141. Wilson N.S., Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, et al. 2011. An Fcg receptor-dependent mechanism drives antibodymediated target-receptor signaling in cancer cells. Cancer Cell 19: 101-113.
142. Wu G.S., Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz I.D., Kao G, Gan DD, Zhou JY, Muschel R, et al. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143.
143. Yeh W.C., Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C., Suzuki N, Bonnard M, Goeddel DV, et al. 2000. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12: 633-642.
144. Yin X.M., Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth K.A., Korsmeyer SJ. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886-891.
145. Yonehara S., Ishii A, Yonehara M. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756.
146. Yuan J.Y., Horvitz HR. 1990. The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 138: 33-41.
147. Yuan J., Shaham S, Ledoux S, Ellis HM, Horvitz HR. 1993. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 β-converting enzyme. Cell 75: 641-652.
148. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. 2009. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325: 332-336.
149. Zhang H., Zhou X, McQuade T, Li J, Chan FK, Zhang J. 2011. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471: 373-376.